{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:53Z","timestamp":1790834273262,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02199-x","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T08:34:01Z","timestamp":1657614841000},"page":"4374-4390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rog\u00e9rio","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K. S.","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neli","family":"Boyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Chamitava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Channick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/Chest.15-0300","volume":"148","author":"H Farber","year":"2015","unstructured":"Farber H, Miller D, Poms A, Badesch D, Frost A, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the reveal registry. Chest. 2015;148:1043\u201354. https:\/\/doi.org\/10.1378\/Chest.15-0300.","journal-title":"Chest"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1378\/Chest.11-1460","volume":"142","author":"R Benza","year":"2012","unstructured":"Benza R, Miller D, Barst R, Badesch D, Frost A, Mcgoon M. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012;142:448\u201356. https:\/\/doi.org\/10.1378\/Chest.11-1460.","journal-title":"Chest"},{"issue":"37","key":"2199_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/Eurheartj\/Ehv317","volume":"2016","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Jl V, Gibbs S, Lang I, Torbicki A, et al. ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed By: Association For European Paediatric And Congenital Cardiology (Aepc), International Society For Heart And Lung Transplantation (Ishlt). Eur Heart J. 2015;2016(37):67\u2013119. https:\/\/doi.org\/10.1093\/Eurheartj\/Ehv317.","journal-title":"Eur Heart J"},{"key":"2199_CR4","unstructured":"Opsumit\u00ae (Macitentan). Full Prescribing Information. Actelion Pharmaceuticals Us, Inc. March. 2019."},{"key":"2199_CR5","unstructured":"Opsumit\u00ae (Macitentan). Summary Of Product Characteristics. Actelion Pharmaceuticals Ltd. October. 2019."},{"key":"2199_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick R, Delcroix M, Gali\u00e8 N, Ghofrani A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318. https:\/\/doi.org\/10.1056\/nejmoa1213917.","journal-title":"N Engl J Med"},{"key":"2199_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/674456","volume":"3","author":"M Chakinala","year":"2013","unstructured":"Chakinala M, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulm Circ. 2013;3:507\u201322. https:\/\/doi.org\/10.1086\/674456.","journal-title":"Pulm Circ."},{"key":"2199_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/Circulationaha.112.118547","volume":"126","author":"F Hw","year":"2012","unstructured":"Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square peg into a round hole? Circulation. 2012;126:258\u201360. https:\/\/doi.org\/10.1161\/Circulationaha.112.118547.","journal-title":"Circulation"},{"key":"2199_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/Sj.Bjc.6601118","volume":"89","author":"C Tg","year":"2003","unstructured":"Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89:232\u20138. https:\/\/doi.org\/10.1038\/Sj.Bjc.6601118.","journal-title":"Br J Cancer"},{"key":"2199_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/J.Jcmg.2021.07.027","volume":"15","author":"A Vonk Noordegraaf","year":"2022","unstructured":"Vonk Noordegraaf A, Channick R, Cottreel E, Kiely D, Marcus J, Martin N, et al. The repair study: effects of macitentan on RV structure and function in pulmonary arterial hypertension. JACC Cardiovasc Imaging. 2022;15:240\u201353. https:\/\/doi.org\/10.1016\/J.Jcmg.2021.07.027.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2199_CR11","doi-asserted-by":"publisher","first-page":"Pa5458","DOI":"10.1183\/13993003.01508-2019","volume":"54","author":"N Kim","year":"2019","unstructured":"Kim N, Channick R, Chin K, Melendres-Groves L, Ravichandran A, Brand M, et al. Macitentan in pulmonary hypertension (PH): data from opus and orpheus real-world data sets. Eur Respir J. 2019;54:Pa5458. https:\/\/doi.org\/10.1183\/13993003.congress-2019.PA5458","journal-title":"Eur Respir J"},{"key":"2199_CR12","doi-asserted-by":"publisher","first-page":"A870","DOI":"10.1016\/J.Chest.2019.08.825","volume":"156","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Canuet M, Picard F, Gregoire P, Bergot E, Cottin V, et al. Initial treatment combination with macitentan and tadalafil in patients with pulmonary arterial hypertension: results from the optima study. Chest. 2019;156:A870\u20131. https:\/\/doi.org\/10.1016\/J.Chest.2019.08.825.","journal-title":"Chest"},{"key":"2199_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/Circulationaha.118.033575","volume":"139","author":"M Gatzoulis","year":"2019","unstructured":"Gatzoulis M, Landzberg M, Beghetti M, Berger R, Efficace M, Gesang S, et al. Evaluation of macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139:51\u201363. https:\/\/doi.org\/10.1161\/Circulationaha.118.033575.","journal-title":"Circulation"},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","volume":"7","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Bosch J, Cottreel E, Csonka D, De Groote P, Hoeper M, et al. Macitentan for the treatment of portopulmonary hypertension (Portico): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7:594\u2013604. https:\/\/doi.org\/10.1016\/S2213-2600(19)30091-8.","journal-title":"Lancet Respir Med"},{"key":"2199_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","volume":"5","author":"H-A Ghofrani","year":"2017","unstructured":"Ghofrani H-A, Simonneau G, D\u2019armini A, Fedullo P, Howard L, Jais X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (Merit-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785\u201394. https:\/\/doi.org\/10.1016\/S2213-2600(17)30305-3.","journal-title":"Lancet Respir Med"},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","volume":"50","author":"M Hoeper","year":"2017","unstructured":"Hoeper M, Kramer T, Pan Z, Eichstaedt C, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740. https:\/\/doi.org\/10.1183\/13993003.00740-2017.","journal-title":"Eur Respir J"},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/J.Healun.2011.08.019","volume":"30","author":"R Benza","year":"2011","unstructured":"Benza R, Seeger W, Mclaughlin V, Channick R, Voswinckel R, Tapson V, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (triumph) study open-label extension. J Heart Lung Transplant. 2011;30:1327\u201333. https:\/\/doi.org\/10.1016\/J.Healun.2011.08.019.","journal-title":"J Heart Lung Transplant"},{"key":"2199_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","volume":"4","author":"H Ghofrani","year":"2016","unstructured":"Ghofrani H, Grimminger F, Grunig E, Huang Y, Jansa P, Jing Z, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the patent-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4:361\u201371. https:\/\/doi.org\/10.1016\/S2213-2600(16)30019-4.","journal-title":"Lancet Respir Med"},{"key":"2199_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/J.Healun.2014.02.019","volume":"33","author":"G Simonneau","year":"2014","unstructured":"Simonneau G, Rubin L, Gali\u00e8 N, Barst R, Fleming T, Frost A, et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33:689\u201397. https:\/\/doi.org\/10.1016\/J.Healun.2014.02.019.","journal-title":"J Heart Lung Transplant"},{"key":"2199_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/Chest.10-0969","volume":"140","author":"L Rubin","year":"2011","unstructured":"Rubin L, Badesch D, Fleming T, Galie N, Simonneau G, Ghofrani H, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the super-2 study. Chest. 2011;140:1274\u201383. https:\/\/doi.org\/10.1378\/Chest.10-0969.","journal-title":"Chest"},{"key":"2199_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/S12325-021-01898-1","author":"N Gali\u00e8","year":"2021","unstructured":"Gali\u00e8 N, Gaine S, Channick R, Coghlan J, Hoeper M, Lang I, et al. Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from griphon and its open-label extension. Adv Ther. 2021. https:\/\/doi.org\/10.1007\/S12325-021-01898-1.","journal-title":"Adv Ther"},{"key":"2199_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/S00408-020-00402-W","volume":"198","author":"G Heresi","year":"2020","unstructured":"Heresi G, Rao Y. Follow-up functional class and 6-minute walk distance identify long-term survival in pulmonary arterial hypertension. Lung. 2020;198:933\u20138. https:\/\/doi.org\/10.1007\/S00408-020-00402-W.","journal-title":"Lung"},{"key":"2199_CR23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"S Pocock","year":"2002","unstructured":"Pocock S, Clayton T, Altman D. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08594-X.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:57:32Z","timestamp":1661335052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02199-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}